vs
Side-by-side financial comparison of BTCS Inc. (BTCS) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $7.1M, roughly 1.3× BTCS Inc.). On growth, BTCS Inc. posted the faster year-over-year revenue change (205.5% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-9.8M). Over the past eight quarters, BTCS Inc.'s revenue compounded faster (296.4% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
BTCS vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.1M | $9.1M |
| Net Profit | — | $-5.5M |
| Gross Margin | 12.4% | 49.4% |
| Operating Margin | — | -51.1% |
| Net Margin | — | -60.3% |
| Revenue YoY | 205.5% | -49.9% |
| Net Profit YoY | — | -184.8% |
| EPS (diluted) | $-1.58 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.1M | $9.1M | ||
| Q3 25 | $4.9M | $17.9M | ||
| Q2 25 | $2.8M | $15.7M | ||
| Q1 25 | $1.7M | $10.1M | ||
| Q4 24 | $2.3M | $18.2M | ||
| Q3 24 | $739.2K | $18.0M | ||
| Q2 24 | $561.2K | $13.5M | ||
| Q1 24 | $451.4K | — |
| Q4 25 | — | $-5.5M | ||
| Q3 25 | $65.6M | $2.4M | ||
| Q2 25 | $3.9M | $164.0K | ||
| Q1 25 | $-17.3M | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | $-9.0M | $3.2M | ||
| Q2 24 | $-6.7M | $-2.2M | ||
| Q1 24 | $12.3M | — |
| Q4 25 | 12.4% | 49.4% | ||
| Q3 25 | 22.0% | 53.4% | ||
| Q2 25 | -2.9% | 62.5% | ||
| Q1 25 | 7.1% | 19.1% | ||
| Q4 24 | 2.9% | 78.7% | ||
| Q3 24 | 26.5% | 53.4% | ||
| Q2 24 | 69.9% | 29.8% | ||
| Q1 24 | 64.4% | — |
| Q4 25 | — | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q1 24 | — | — |
| Q4 25 | — | -60.3% | ||
| Q3 25 | 1328.1% | 13.2% | ||
| Q2 25 | 140.0% | 1.0% | ||
| Q1 25 | -1022.5% | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | -1223.0% | 18.0% | ||
| Q2 24 | -1198.9% | -16.4% | ||
| Q1 24 | 2715.3% | — |
| Q4 25 | $-1.58 | $-0.06 | ||
| Q3 25 | $1.30 | $0.03 | ||
| Q2 25 | $0.14 | $0.00 | ||
| Q1 25 | $-0.86 | $-0.05 | ||
| Q4 24 | $0.28 | $0.10 | ||
| Q3 24 | $-0.56 | $0.03 | ||
| Q2 24 | $-0.43 | $-0.03 | ||
| Q1 24 | $0.63 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.5M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.4M | $48.2M |
| Total Assets | $214.6M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.5M | $14.7M | ||
| Q3 25 | $4.5M | $13.6M | ||
| Q2 25 | $639.2K | $17.9M | ||
| Q1 25 | $269.9K | $19.5M | ||
| Q4 24 | $2.0M | $19.8M | ||
| Q3 24 | $254.5K | $27.4M | ||
| Q2 24 | $536.7K | $23.4M | ||
| Q1 24 | $670.6K | — |
| Q4 25 | $139.4M | $48.2M | ||
| Q3 25 | $225.4M | $52.9M | ||
| Q2 25 | $31.1M | $49.9M | ||
| Q1 25 | $20.6M | $45.2M | ||
| Q4 24 | $34.0M | $43.2M | ||
| Q3 24 | $25.2M | $32.4M | ||
| Q2 24 | $33.1M | $28.6M | ||
| Q1 24 | $39.3M | — |
| Q4 25 | $214.6M | $82.3M | ||
| Q3 25 | $298.9M | $82.3M | ||
| Q2 25 | $40.8M | $78.5M | ||
| Q1 25 | $21.0M | $73.9M | ||
| Q4 24 | $38.2M | $73.4M | ||
| Q3 24 | $26.5M | $61.6M | ||
| Q2 24 | $33.8M | $91.5M | ||
| Q1 24 | $39.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.8M | $2.0M |
| Free Cash FlowOCF − Capex | $-9.8M | $1.6M |
| FCF MarginFCF / Revenue | -138.1% | 17.8% |
| Capex IntensityCapex / Revenue | 0.2% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-15.8M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-9.8M | $2.0M | ||
| Q3 25 | $-2.8M | $-3.7M | ||
| Q2 25 | $-1.3M | $-5.2M | ||
| Q1 25 | $-1.9M | $-5.1M | ||
| Q4 24 | $-3.5M | $4.0M | ||
| Q3 24 | $-695.2K | $4.1M | ||
| Q2 24 | $-924.1K | $-3.6M | ||
| Q1 24 | $-769.0K | — |
| Q4 25 | $-9.8M | $1.6M | ||
| Q3 25 | $-2.8M | $-4.2M | ||
| Q2 25 | $-1.3M | $-5.7M | ||
| Q1 25 | $-1.9M | $-5.4M | ||
| Q4 24 | $-3.5M | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | -138.1% | 17.8% | ||
| Q3 25 | -56.7% | -23.7% | ||
| Q2 25 | -48.2% | -36.2% | ||
| Q1 25 | -112.7% | -53.0% | ||
| Q4 24 | -152.2% | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | 0.2% | 4.4% | ||
| Q3 25 | 0.1% | 2.8% | ||
| Q2 25 | 0.1% | 2.8% | ||
| Q1 25 | 0.1% | 3.0% | ||
| Q4 24 | 0.1% | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | -1.58× | ||
| Q2 25 | -0.34× | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.06× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BTCS
| Builder Plus | $5.9M | 83% |
| Other | $1.2M | 17% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
